vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and Eightco Holdings Inc. (ORBS). Click either name above to swap in a different company.
AGIOS PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($20.0M vs $10.2M, roughly 2.0× Eightco Holdings Inc.). AGIOS PHARMACEUTICALS, INC. runs the higher net margin — -541.1% vs -2281.6%, a 1740.5% gap on every dollar of revenue. On growth, AGIOS PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (86.1% vs -49.9%). Eightco Holdings Inc. produced more free cash flow last quarter ($-11.0M vs $-97.3M). Over the past eight quarters, AGIOS PHARMACEUTICALS, INC.'s revenue compounded faster (56.1% CAGR vs 13.1%).
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
AGIO vs ORBS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.0M | $10.2M |
| Net Profit | $-108.0M | $-232.5M |
| Gross Margin | 90.6% | -13.0% |
| Operating Margin | -608.9% | -475.0% |
| Net Margin | -541.1% | -2281.6% |
| Revenue YoY | 86.1% | -49.9% |
| Net Profit YoY | -11.9% | -9183.3% |
| EPS (diluted) | $-1.86 | $-2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.0M | $10.2M | ||
| Q3 25 | $12.9M | $5.3M | ||
| Q2 25 | $12.5M | $7.6M | ||
| Q1 25 | $8.7M | $9.9M | ||
| Q4 24 | $10.7M | $20.3M | ||
| Q3 24 | $9.0M | $6.1M | ||
| Q2 24 | $8.6M | $5.3M | ||
| Q1 24 | $8.2M | $8.0M |
| Q4 25 | $-108.0M | $-232.5M | ||
| Q3 25 | $-103.4M | $-25.8M | ||
| Q2 25 | $-112.0M | $-1.2M | ||
| Q1 25 | $-89.3M | $-2.5M | ||
| Q4 24 | $-96.5M | $-2.5M | ||
| Q3 24 | $947.9M | $-3.2M | ||
| Q2 24 | $-96.1M | $4.4M | ||
| Q1 24 | $-81.5M | $1.9M |
| Q4 25 | 90.6% | -13.0% | ||
| Q3 25 | 87.0% | -3.7% | ||
| Q2 25 | 86.3% | 16.4% | ||
| Q1 25 | 87.6% | 8.2% | ||
| Q4 24 | 88.3% | 8.2% | ||
| Q3 24 | 91.3% | 26.5% | ||
| Q2 24 | 82.6% | 25.1% | ||
| Q1 24 | 92.3% | 17.5% |
| Q4 25 | -608.9% | -475.0% | ||
| Q3 25 | -907.4% | -116.9% | ||
| Q2 25 | -1020.1% | -15.9% | ||
| Q1 25 | -1222.0% | -14.3% | ||
| Q4 24 | -1165.3% | -11.9% | ||
| Q3 24 | -1146.9% | -29.1% | ||
| Q2 24 | -1228.3% | -16.4% | ||
| Q1 24 | -1124.3% | -39.6% |
| Q4 25 | -541.1% | -2281.6% | ||
| Q3 25 | -803.1% | -487.6% | ||
| Q2 25 | -899.4% | -15.4% | ||
| Q1 25 | -1023.3% | -25.7% | ||
| Q4 24 | -899.6% | -12.3% | ||
| Q3 24 | 10574.7% | -52.5% | ||
| Q2 24 | -1115.7% | 84.2% | ||
| Q1 24 | -995.8% | 24.4% |
| Q4 25 | $-1.86 | $-2.34 | ||
| Q3 25 | $-1.78 | $-0.58 | ||
| Q2 25 | $-1.93 | $-0.38 | ||
| Q1 25 | $-1.55 | $-0.84 | ||
| Q4 24 | $-1.44 | $-1.44 | ||
| Q3 24 | $16.22 | $-1.77 | ||
| Q2 24 | $-1.69 | $2.15 | ||
| Q1 24 | $-1.45 | $1.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.1M | $58.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $232.6M |
| Total Assets | $1.3B | $250.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.1M | $58.5M | ||
| Q3 25 | $92.7M | $23.7M | ||
| Q2 25 | $80.9M | $696.3K | ||
| Q1 25 | $79.0M | $434.4K | ||
| Q4 24 | $76.2M | $239.2K | ||
| Q3 24 | $253.7M | $2.4M | ||
| Q2 24 | $84.5M | $363.1K | ||
| Q1 24 | $118.8M | $808.8K |
| Q4 25 | $1.2B | $232.6M | ||
| Q3 25 | $1.3B | $339.2M | ||
| Q2 25 | $1.4B | $8.9M | ||
| Q1 25 | $1.5B | $9.7M | ||
| Q4 24 | $1.5B | $11.9M | ||
| Q3 24 | $1.6B | $13.0M | ||
| Q2 24 | $660.5M | $13.8M | ||
| Q1 24 | $743.9M | $3.9M |
| Q4 25 | $1.3B | $250.2M | ||
| Q3 25 | $1.4B | $355.5M | ||
| Q2 25 | $1.5B | $48.7M | ||
| Q1 25 | $1.6B | $47.6M | ||
| Q4 24 | $1.7B | $50.8M | ||
| Q3 24 | $1.8B | $49.2M | ||
| Q2 24 | $773.1M | $48.4M | ||
| Q1 24 | $849.7M | $50.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-96.2M | $-11.0M |
| Free Cash FlowOCF − Capex | $-97.3M | $-11.0M |
| FCF MarginFCF / Revenue | -487.5% | -107.7% |
| Capex IntensityCapex / Revenue | 5.6% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-377.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-96.2M | $-11.0M | ||
| Q3 25 | $-88.2M | $-1.6M | ||
| Q2 25 | $-77.1M | $-659.2K | ||
| Q1 25 | $-111.5M | $999.8K | ||
| Q4 24 | $-133.2M | $-6.6M | ||
| Q3 24 | $-84.2M | $77.7K | ||
| Q2 24 | $-72.6M | $-440.3K | ||
| Q1 24 | $-99.9M | $-723.3K |
| Q4 25 | $-97.3M | $-11.0M | ||
| Q3 25 | $-89.7M | — | ||
| Q2 25 | $-78.0M | $-661.3K | ||
| Q1 25 | $-112.3M | $999.7K | ||
| Q4 24 | $-134.1M | $-6.6M | ||
| Q3 24 | $-84.6M | $73.0K | ||
| Q2 24 | $-72.7M | — | ||
| Q1 24 | $-100.0M | — |
| Q4 25 | -487.5% | -107.7% | ||
| Q3 25 | -696.5% | — | ||
| Q2 25 | -626.2% | -8.7% | ||
| Q1 25 | -1286.4% | 10.1% | ||
| Q4 24 | -1250.1% | -32.7% | ||
| Q3 24 | -944.2% | 1.2% | ||
| Q2 24 | -844.4% | — | ||
| Q1 24 | -1221.2% | — |
| Q4 25 | 5.6% | 0.0% | ||
| Q3 25 | 12.1% | 0.0% | ||
| Q2 25 | 7.0% | 0.0% | ||
| Q1 25 | 8.8% | 0.0% | ||
| Q4 24 | 9.0% | 0.0% | ||
| Q3 24 | 4.7% | 0.1% | ||
| Q2 24 | 1.8% | — | ||
| Q1 24 | 1.7% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.09× | — | ||
| Q2 24 | — | -0.10× | ||
| Q1 24 | — | -0.37× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
